IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Horizon Pharma plc (“Horizon” or the “Company”) (Nasdaq: HZNP). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of Horizon during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The investigation will focus on the February 29, 2016 annual report released by Horizon concerning a subpoena it received in November of 2015. Horizon stated that it had received the subpoena from the U.S. Attorney for the Southern District of New York concerning its paid assistance programs.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.